69.68BMarket Cap16.62P/E (TTM)
642.970High631.450Low805.92KVolume638.010Open635.830Pre Close514.27MTurnover0.77%Turnover Ratio16.62P/E (Static)109.32MShares1209.63752wk High2.37P/B67.11BFloat Cap629.02052wk Low--Dividend TTM105.30MShs Float1209.637Historical High--Div YieldTTM1.81%Amplitude4.604Historical Low638.118Avg Price1Lot Size
Regeneron Pharmaceuticals Stock Forum
Can Dupixent Transform Rare Skin Disease Treatment? New Trial Data Reveals Breakthrough
Regeneron's Multiple Myeloma Drug Clears Critical EU Regulatory Hurdle - What's Next?
Can Regeneron's Cancer Drug With 80% Response Rate Secure FDA Approval For Lymphoma?
Revolutionary Hearing Breakthrough: Can This Gene Therapy End Childhood Genetic Deafness?
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
No comment yet